Physician Advisory Board

Rebiotix works closely with a panel of physician advisors in the fields of infectious diseases, gastroenterology, and medical economics.

Erik Dubberke, MD, MSPH

Erik Dubberke, MD, MSPH is an Associate Professor of Medicine in the Division of Infectious Diseases at Washington University School of Medicine, St. Louis, MO where he specializes in epidemiology and infectious diseases. His interests include transplant infectious diseases, infections in oncology patients, C. diff.-associated disease and healthcare epidemiology.

View Dr. Dubberke’s complete bio

Dale N. Gerding, MD, MACP, FIDSA, FSHEA

Dale N. Gerding, MD, MAPCP, FIDSA, FSHEA, is a Professor of Medicine in the Division of Infectious Diseases at Loyola University Chicago Stritch School of Medicine, Maywood, IL and Research Physician at the Hines, Veterans Affairs Hospital, Hines, IL. He specializes in infectious diseases and hospital epidemiology. His research interests include the epidemiology and prevention of C. diff. disease, antimicrobial resistance, and the use of non-toxigenic C. diff. for the prevention and treatment of this disease.

View Dr. Gerding’s complete bio

Gail Hecht, MD

Gail Hecht, MD is a Professor of Medicine and Microbiology/Immunology and Chief, Gastroenterology and Nutrition at Loyola University, Chicago, IL. Dr. Hecht specializes in gastroenterology, microbiology, immunology, and her research interests include the interaction of enteric bacterial pathogens with host intestinal epithelial cells and mechanisms and the impact of the gut microbiome on intestinal function and health. She has investigated host-microbial interactions in the gastrointestinal tract for more than 25 years. Currently, Dr. Hecht also holds the position of Assistant Dean for Medical Student Research and serves as Editor-in-Chief of the journal Gut Microbes.

View Dr. Hecht’s complete bio

Peter T. Kim, PhD

Peter Kim is a Professor of Statistics at the University of Guelph, Guelph, ON, Canada. His work focuses on bioinformatics and biostatistics, mainly in a clinical setting and he has developed protocols for several studies of fecal transplantation. The clinical studies involved assessment of the safety and efficacy of fecal transplant therapy in randomized controlled trials and analysis of the metagenomics involved in pre- and post-transplant gut microbial populations. Additionally, Mr. Kim is interested in the application of statistics and geometry to anatomy in order to better understand the biomechanics involved in movement of the knee joint or the spine.

View Prof. Kim’s complete bio

Christine Lee, MD

Christine Lee, MD is a Professor of Medicine in the Department of Pathology at McMaster University, Hamilton, ON, Canada. Dr. Lee specializes in infectious diseases and medical microbiology. Her interests include optimal laboratory methods to diagnose and treat C. diff.-associated diarrhea and the diagnosis and management of nosocomial infections (intravenous catheter infections, ventilator-associated pneumonia). Her clinical focus includes the treatment of recurrent and refractory C. diff. infection and has organized and led two clinical trials assessing the use of fecal microbiota transplantation (FMT) in gastrointestinal disease.

View Dr. Lee’s complete bio

Sonia Michail, MD

Sonia Michail, MD is an Associate Professor of Pediatrics at the Keck School of Medicine, University of Southern California, Los Angeles, CA. Dr. Michail specializes in pediatric gastroenterology. Her research interests include probiotics and the gut microbiome and she has NIH-funding to study the effect of probiotics on children with irritable bowel syndrome. Dr. Michail is also heading up studies on fecal microbiota transplantation for children with ulcerative colitis and recurrent C. diff. infection.

View Dr. Michail’s complete bio

Robert Orenstein, DO

Robert Orenstein, DO is an Associate Professor of Medicine and the Chair of the Division of Infectious Diseases at Mayo Clinic in Arizona. His clinical research is focused on the prevention and management of healthcare-acquired infections, in particular C. diff. infection. He has helped design systems for the surveillance of C. diff. and interventions to reduce its transmission. He runs one of the nation’s most successful programs for fecal microbiota transplantation for patients with recurrent C. diff.

View Dr. Orenstein’s complete bio